On November 28, gelonhui announced that wuhan hiteck biological pharma (300683.SZ) disclosed that according to the notice issued by the National Medical Insurance Administration and the Ministry of Human Resources and Social Security, "Notice on the Issuance of the National Basic Medical Insurance, Work Injury Insurance, and Maternity Insurance Drug List (2024)" [Medical Insurance No. [2024] 33], wuhan hiteck biological pharmaceutical Co., Ltd. (hereinafter referred to as the "Company") product Epnitinib for injection was included in the "National Basic Medical Insurance, Work Injury Insurance, and Maternity Insurance Drug List (2024)" (hereinafter referred to as the "2024 National Medical Insurance List") for the first time through negotiation.
Injection Epnitinib is a national Class I recombinant protein innovative drug developed by the company, and it is the world's first and only marketed death receptor 4/5 (DR4/DR5) agonist. It is indicated for use in adult patients with relapsed or refractory multiple myeloma who have received at least 2 systemic treatment regimens in the past, in combination with lenalidomide and dexamethasone, and patients difficult to treat with previous immune modulators (such as lenalidomide, lenalidomide) should not receive this combination therapy.
